Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -465.8%. (2019–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $4M | $754M | $4.0B | $3.0B | — | — |
| Enterprise Value | $511671 | $1M | $754M | $4.0B | $3.0B | — | — |
| P/E Ratio → | -0.16 | — | — | — | — | — | — |
| P/S Ratio | 3.89 | 4.68 | 841.61 | 7588.04 | 5190.71 | — | — |
| P/B Ratio | 0.57 | 0.69 | 231.95 | 285.24 | 471.12 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.36 | 842.00 | 7561.78 | 5180.05 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 64.3% | 64.3% | 56.9% | 34.4% | 30.8% | 24.9% | -21.8% |
| Operating Margin | -2091.2% | -2091.2% | -2975.5% | -4990.6% | -1684.4% | -155.2% | -327.6% |
| Net Profit Margin | -2421.8% | -2421.8% | -2936.5% | -4992.2% | -2024.8% | -118.9% | -340.1% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -465.8% | -465.8% | -303.2% | -258.6% | -645.9% | — | — |
| ROA | -151.2% | -151.2% | -147.5% | -174.7% | -218.2% | -84.5% | -133.7% |
| ROIC | -419.7% | -419.7% | -1056.9% | -10104.6% | -4482.9% | -306.2% | — |
| ROCE | -277.8% | -277.8% | -240.4% | -214.2% | -224.6% | -673.3% | -359.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.54 | 0.54 | 2.28 | 0.23 | 0.41 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.49 | 0.11 | -0.99 | -0.97 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -17.39 | -17.39 | -32.91 | -91.40 | -28.67 | -2.85 | -4.57 |
Net cash position: cash ($6M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.32 | 1.32 | 0.97 | 4.33 | 7.11 | 0.27 | 0.57 |
| Quick Ratio | 1.26 | 1.26 | 0.91 | 4.29 | 7.11 | 0.27 | 0.57 |
| Cash Ratio | 1.05 | 1.05 | 0.77 | 4.04 | 6.46 | 0.17 | 0.44 |
| Asset Turnover | — | 0.07 | 0.06 | 0.03 | 0.06 | 0.73 | 0.39 |
| Inventory Turnover | 0.86 | 0.86 | 0.63 | 1.98 | — | — | — |
| Days Sales Outstanding | — | 87.27 | 144.50 | 178.50 | 11.23 | 32.72 | 52.92 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $968234 | $16M | $14M | $7M | $6M | $12M |
Capital exhaustion and dilution
Based on reported figures, the company trades at a price-to-sales ratio of 3.89, which appears disconnected from its negligible revenue base and suggests that market participants are pricing the equity as a high-risk option on future clinical trial success rather than current commercial performance.
The current valuation multiple reflects a significant premium relative to the company's lack of profitability and stagnant revenue growth. Investors should monitor whether this valuation can be sustained as the company approaches potential liquidity events, given that the P/S ratio provides little support in the absence of a clear path to positive cash flow.
According to historical financial data, the company's ROIC has remained deeply negative, fluctuating between -2.1% and -171.5% over the last ten quarters, indicating that capital deployed into clinical and commercial initiatives has yet to generate any meaningful economic return for shareholders.
The inability to achieve positive returns on invested capital suggests that the current business model is structurally inefficient at this scale. This trend warrants further investigation into whether the company can ever achieve the necessary operating leverage to turn these negative returns into a sustainable compounding engine.
As reported in recent financial statements, the company's cash conversion cycle remains highly erratic and deeply negative, with DSO reaching 209 days in 2024Q4, which highlights significant friction in collecting payments from laboratory partners and managing the overall diagnostic kit supply chain.
The extreme volatility in the cash conversion cycle suggests that the decentralized laboratory model may be creating unforeseen administrative and logistical burdens. Investors should monitor whether these inefficiencies are temporary teething issues or structural flaws that will continue to impede the company's ability to manage its working capital effectively.
Based on the 2024Q4 balance sheet, the current ratio of 1.32, when paired with a limited cash position of $6.2 million, indicates a vulnerable liquidity profile that leaves the company with little margin for error in its ongoing clinical and commercial expansion efforts.
The company's reliance on external financing is underscored by its inability to maintain a robust liquidity buffer, making it highly sensitive to capital market conditions. This precarious position suggests that the firm may be forced into dilutive equity raises if it cannot rapidly improve its cash generation capabilities.
The most commonly misapplied ratio for this business model is the price-to-sales multiple, which obscures the company's true financial health by ignoring the massive disconnect between current revenue and the high-burn, research-heavy cost structure required to maintain its decentralized diagnostic platform.
Instead of relying on P/S, analysts should focus on the cash runway and the burn rate relative to clinical milestones, as these metrics provide a more accurate assessment of the company's survival probability. Using revenue multiples in this context risks overestimating the company's commercial maturity and underestimating the dilution risk inherent in its current funding model.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MYNZ stock.
Mainz Biomed B.V.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Mainz Biomed B.V.'s return on equity (ROE) is -465.8%. The historical average is -342.5%.
Based on historical data, Mainz Biomed B.V. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Mainz Biomed B.V. has 64.3% gross margin and -2091.2% operating margin.